Abstract
Parkinson’s disease (PD) and cancer are often thought of as two sides of the same coin. At first glance, cancer and PD appear to have little in common. PD is caused by the degeneration of dopaminergic neurons, whereas cancer results from the uninhibited growth of tumor cells. Increasing numbers of genetic studies suggest that the pathogenesis of PD and cancer may involve similar genes, pathways, and mechanisms. The differences in the pathological and cellular mechanisms, and the associated genetic mutations, may result in two such divergent diseases. In this article, we highlight some molecular mechanisms and key biomarkers which might cause those two diseases from misfolding and degradation of proteins, mitochondrial damage, oxidative stress response, cell cycle control and DNA repair, and the PI3K/AKT/ mTOR pathway, in order to provide help to the understanding and treatment of these two diseases.
Keywords: Cancer, genes, parkinson’s disease, pathways.
Current Cancer Drug Targets
Title:Genetic Predisposition to Parkinson’s Disease and Cancer
Volume: 14 Issue: 3
Author(s): Zhiming Li, Qing Lin, Qilin Ma, Congxia Lu and Chi-Meng Tzeng
Affiliation:
Keywords: Cancer, genes, parkinson’s disease, pathways.
Abstract: Parkinson’s disease (PD) and cancer are often thought of as two sides of the same coin. At first glance, cancer and PD appear to have little in common. PD is caused by the degeneration of dopaminergic neurons, whereas cancer results from the uninhibited growth of tumor cells. Increasing numbers of genetic studies suggest that the pathogenesis of PD and cancer may involve similar genes, pathways, and mechanisms. The differences in the pathological and cellular mechanisms, and the associated genetic mutations, may result in two such divergent diseases. In this article, we highlight some molecular mechanisms and key biomarkers which might cause those two diseases from misfolding and degradation of proteins, mitochondrial damage, oxidative stress response, cell cycle control and DNA repair, and the PI3K/AKT/ mTOR pathway, in order to provide help to the understanding and treatment of these two diseases.
Export Options
About this article
Cite this article as:
Li Zhiming, Lin Qing, Ma Qilin, Lu Congxia and Tzeng Chi-Meng, Genetic Predisposition to Parkinson’s Disease and Cancer, Current Cancer Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1568009614666140312145936
DOI https://dx.doi.org/10.2174/1568009614666140312145936 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Digital Mammograms with Image Enhancement Techniques for Breast Cancer Detection: A Systematic Review
Current Medical Imaging Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design Present Drug Therapy of Demyelinating Disorders
Current Drug Therapy Emerging Drugs for the Treatment of Breast Cancer Brain Metastasis: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Bioconversion of Isoflavones into Bioactive Equol: State of the Art
Recent Patents on Food, Nutrition & Agriculture Effects of Estrogen in the Brain: Is it a Neuroprotective Agent in Alzheimers Disease?
Current Aging Science The ABC of the Blood-Brain Barrier - Regulation of Drug Efflux Pumps
Current Pharmaceutical Design A Novel Bromomelatonin Derivative Suppresses Apoptosis with Regulating the Expression of Bcl-2 Family Genes
Letters in Drug Design & Discovery Profiling of Autophagy-Associated microRNAs in the Osteosarcoma Cell Line of U2OS
Anti-Cancer Agents in Medicinal Chemistry RAS Pathways in Prostate Cancer - Mediators of Hormone Resistance?
Current Cancer Drug Targets Antifertility Activity of Lac (Laccifer lacca Kerr.) in Female Wistar Rat Model
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Clinical Trials in Children
Reviews on Recent Clinical Trials Inhibition of Human Aromatase by Myosmine
Drug Metabolism Letters Key Sites for P2X Receptor Function and Multimerization: Overview of Mutagenesis Studies on a Structural Basis
Current Medicinal Chemistry Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Tumoral Drug Metabolism: Perspectives and Therapeutic Implications
Current Drug Metabolism β-Cyclodextrin Complexes of Hydrolyzable Adamantanoyl-IUdR Prodrugs - Radioiodination and Biodistribution in Mice Bearing Implanted KBALB Tumours
Current Radiopharmaceuticals Phage Display Technology and its Applications in Cancer Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Graphical Abstracts
Current Drug Delivery Integrins: A Method of Early Intervention in the Treatment of Colorectal Liver Metastases
Current Pharmaceutical Design